Xilio Doses First Patient In XTX501 Cancer Trial; Plans 2027 Data Readout
Xilio Therapeutics, Inc. (XLO), a clinical-stage biotechnology company developing masked immuno-oncology therapies, reported third-quarter 2026 financial results Tuesday and provided updates on its clinical and preclinical pipeline. The company dosed the …